Quick Takeaways
- This page summarizes Jerome M. Adams's Form 4 filing for Atea Pharmaceuticals, Inc. (AVIR).
- 2 reported transactions and 2 derivative rows are listed below.
- Filing timestamp: 21 Jun 2024, 18:06.
Jerome M. Adams - 21 Jun 2024 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)
- Role
- Director
- Signature
- /s/ Andrea Corcoran, as Attorney-in-Fact for Jerome M. Adams
- Issuer symbol
- AVIR
- Transactions as of
- 21 Jun 2024
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 21 Jun 2024, 18:06:14 UTC
- Previous filing
- 18 Jun 2024
- Next filing
- 24 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Jerome M. Adams filed Form 4 for Atea Pharmaceuticals, Inc. (AVIR) on 21 Jun 2024."
What Changed
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AVIR | Restricted Stock Units | Award | $0 | +29,600 | $0.000000 | 29,600 | 21 Jun 2024 | Common Stock | 29,600 | Direct | F1, F2 | ||
| transaction | AVIR | Stock Option (Right to Buy) | Award | $0 | +41,200 | $0.000000 | 41,200 | 21 Jun 2024 | Common Stock | 41,200 | $3.44 | Direct | F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Restricted stock units convert into common stock on a one-for-one basis. |
| F2 | The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. |
| F3 | The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. |